&w=3840&q=100)
Emcure enters distribution agreement with Sanofi for diabetes drugs
Emcure added that it will engage with healthcare professionals and expand the reach of these therapeutic solutions for patients across the country.
Sanket Koul New Delhi
Pune-based Emcure Pharmaceuticals on Wednesday announced an exclusive distribution and promotion agreement with Sanofi India (SIL) for its oral anti-diabetic (OAD) products in India.
Under the agreement, SIL will continue to own and manufacture the brands across its plants in India and internationally, while Emcure will exclusively distribute and promote SIL's OAD range, which includes well-established brands such as Amaryl and Cetapin.
There will be no employee transition from SIL to Emcure as part of this arrangement, the Pune-based drugmaker said in a regulatory filing to the exchanges.
Emcure added that it will engage with healthcare professionals and expand the reach of these therapeutic solutions for patients across the country.
'With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them,' he added.
Over 100 million Indians are currently living with type 2 diabetes and its associated complications, according to a study by the Indian Council of Medical Research–INDIAB (India Diabetes).
'Of these, more than 60 per cent are living with uncontrolled blood sugar levels and are at higher risk of developing complications over time,' said Eric Mansion, general manager (pharma) for Southeast Asia and India at Sanofi.
He added that with Emcure's wide and deeply penetrated presence across India, the company is confident of tapping the full growth potential of Amaryl and Cetapin.
The announcement was made post market hours. On Wednesday, shares of Emcure Pharmaceuticals closed marginally higher by 0.22 per cent at Rs 1,363.85 apiece on the Bombay Stock Exchange (BSE).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
an hour ago
- The Print
Former chief justice of India Chandrachud says Viceroy report on Vedanta Group lacks credibility
According to the filing, the former CJI has opined that 'Viceroy has a track record of taking short positions in listed companies and then publishing misleading reports to profit unlawfully from the resulting market impact'. Justice Chandrachud's remark came after Vedanta sought an independent legal opinion from the former chief justice in relation to the allegations made in the Viceroy Research report, the company said in a regulatory filing on Friday. New Delhi, Jul 19 (PTI) US short seller Viceroy Research's report on the Vedanta Group 'lacks credibility' and the firm would be well-placed to seek legal remedies, former chief justice of India D Y Chandrachud has said. The Viceroy Research's report on the company contains serious allegations, causing harm to the Vedanta Group's business and reputation, Justice Chandrachud said. 'The report contains serious imputations such as 'ponzi scheme' and 'parasite', which have caused harm to querist's (Vedanta's) business and reputation,' he said, adding, 'in these circumstances, the querist would be well-placed to seek legal remedies.' The US short seller in its July 9 report had called billionaire Anil Agarwal-led British firm Vedanta Resources a 'parasite' that is 'systematically draining' its Indian unit, an allegation which the group called as 'selective misinformation and baseless' aimed at discrediting the firm. Viceroy Research took a short position against the debt of Vedanta Resources, the UK-based parent of Indian miner Vedanta Ltd, alleging that the group 'is a house of cards built on a foundation of unsustainable debt, looted assets, and accounting fiction'. Vedanta had responded, saying the report was 'a malicious combination of selective misinformation and baseless allegations' and that its authors issued it without contacting the group. PTI SID HVA This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Mint
an hour ago
- Mint
AU Small Finance Bank Q1 Results: Net profit rises 16% at ₹581 crore, asset quality deteriorates
AU Small Finance Bank on Saturday announced its earnings report for the first quarter (Q1) ended June 30, 2025 of the fiscal year 2026. The Jaipur-based bank said its net profit rose 16% at ₹ 581 crore during the first quarter of this financial year, as compared to ₹ 503 crore in the same period of the previous fiscal year. Its total income stood at ₹ 5,189 crore during the June 2025 quarter, up from ₹ 4,278 crore in the same period a year ago. Net interest income (NII) surged to ₹ 2,045 crore in the reported quarter against ₹ 1,921 crore a year ago. Interest earned by the lender increased to ₹ 4,378 crore when compared with ₹ 3,769 crore in the June quarter of FY25. AU Small Finance Bank's operating profit jumped to ₹ 1,312 crore in Q1 of FY26 from ₹ 952 crore in the same period last fiscal year. AU Small Finance Bank MD and CEO Sanjay Agarwal said: "We have reported another set of consistent performance in a seasonally soft quarter, showing sustainable growth in deposits, assets, and profitability". As the economic cycle strengthens, AU is well-positioned to navigate near-term uncertainties while staying committed to the long-term vision of building a forever bank that can truly scale with sustainability, he added. Its asset quality deteriorated, as gross non-performing assets (NPAs) rose to 2.47% of gross advances at the end of the June quarter, from 1.78% a year ago. Gross loan portfolio (GLP) rose 18% to ₹ 117,624 crore in Q1 FY25, as compared to ₹ 99,792 crore last year. Similarly, net NPAs, or bad loans, increased to 0.88% against 0.63% in the year ago period. As a result, provisions and contingencies almost doubled to ₹ 533 crore during the first quarter, when compared to ₹ 283 crore a year ago.
The Hindu
an hour ago
- The Hindu
Union Bank of India logs 12% rise in net to ₹4,116 crore in Q1
State-owned Union Bank of India on Saturday (July 19, 2025) reported a 12% rise in net profit to ₹4,116 crore during the first quarter of this financial year. The Mumbai-based lender had earned a net profit of ₹3,679 crore in the same quarter of the previous fiscal year. The total income rose to ₹31,791 crore during the June 2025 quarter from ₹30,874 crore in the year-ago period, Union Bank of India said in a regulatory filing. Interest earned by the bank improved to ₹27,296 crore compared to ₹26,364 crore in the June quarter of FY25. However, net interest income declined to ₹9,113 crore during the quarter against ₹9,412 crore a year ago. The bank's operating profit also dropped 11% to ₹6,909 crore from ₹7,785 crore in the same quarter of the preceding fiscal. The bank's asset quality showed improvement as gross non-performing assets (NPAs) declined to 3.52% of gross advances at the end of the June quarter from 4.54% a year ago. Its gross advance increased by 6.83% to ₹9,74,489 crore from ₹9,12,214 crore at the end of June 2024. Similarly, its net NPAs, or bad loans, declined to 0.62% against 0.90% in the year-ago period. As a result, provisions for bad loans declined to ₹1,153 crore during the first quarter compared to ₹1,651 crore a year ago. Provision Coverage Ratio (PCR) improved to 94.65% from 93.49%, an improvement of 116 bps. At the same time, Return on Assets (ROA) rose to 1.11% for June 2025, from 1.06% in June 2024, registering an improvement of 5 bps, the lender said. Capital adequacy ratio of the bank rose to 18.3% from 17.02% in the same quarter of FY25. The total business grew by 5% to ₹22,14,422 crore from ₹21,08,762 crore at the end of June 2024.
